You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

1466 Results
Regimen
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI), 
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Funding:
ODB - General Benefit
    lanreotide
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
ODB - General Benefit
    letrozole
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
ODB - General Benefit (with Therapeutic Notes)
    procarbazine
ODB - General Benefit
    prednisone
Nov 2017
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Curative
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
Regimen
Intent: Palliative
Nov 2024
Regimen
Intent: Palliative
Jul 2023

Pages